[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362363-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362363-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fam135b-deficiency-inhibits-cytotoxic-t-cell-activity-in-triple-negative-breast-cancer-inhibits-cytotoxic-t-cell-activity","FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer - Inhibits Cytotoxic T-cell Activity","","FAM135B is identified as a regulator of antitumor immunity in triple-negative breast cancer (TNBC). Using single-cell sequencing and functional assays, the study shows that FAM135B activates cytotoxic T cells and improves immune checkpoint blockade (ICB) efficacy through stimulation of the IFI16-dependent STING pathway. Mechanistically, FAM135B interacts with IFI16, blocking TRIM21-mediated ubiquitination and proteasomal degradation, and enabling STING signaling. Deubiquitination of IFI16 at lysine 143 and lysine 561 is crucial. FAM135B may predict ICB responses in TNBC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fam135b-deficiency-inhibits-cytotoxic-t-cell-activity-in-triple-negative-breast-cancer-inhibits-cytotoxic-t-cell-activity/362363/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fam135b-deficiency-inhibits-cytotoxic-t-cell-activity-in-triple-negative-breast-cancer-inhibits-cytotoxic-t-cell-activity/362363.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does FAM135B play in triple-negative breast cancer immunity?","Question",{"text":63,"@type":64},"FAM135B acts as a regulator of antitumor immunity in TNBC by activating cytotoxic T cells and supporting effective immune checkpoint blockade responses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does FAM135B activate the STING pathway?",{"text":68,"@type":64},"FAM135B interacts with IFI16 and inhibits its ubiquitination and proteasomal degradation, initiating IFI16-dependent STING signaling that increases cytotoxic T-cell activity.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are IFI16 deubiquitination sites important?",{"text":72,"@type":64},"Deubiquitination of IFI16 at lysine 143 and lysine 561 is crucial for FAM135B-mediated activation of the STING pathway and subsequent immune activation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362363,1790211430,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the  \nIFI16-Dependent STING Pathway  \nWanmei Lin1,2, Junze Li1,2, Jun Wu2,3, Bin Huang1, Junguang Liang1, Yuan Zhang1, Liang Zhao4,2, and Guangyu Yao1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Immune checkpoint blockade (ICB) has improved outcomes for patients with several types of cancer. However, only a minority of patients with triple-negative breast cancer (TNBC) derive benefits, and the underlying mechanisms remain largely unknown. In this study, we identified family with sequence similarity 135 member B (FAM135B) as a regulator of antitumor immunity in TNBC. Single-cell sequencing data and functional assays demonstrated the critical role of FAM135B in activating cytotoxic T cells and improving the efficacy of ICB treatment by stimulating the STING pathway. Specifically, we found that\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | FAM135B interacts with IFI16, inhibiting its ubiquitination and proteasomal degradation by competitively blocking its binding to the E3 ligase TRIM21 . This initiated IFI16-dependent STING signaling, which ultimately led to increased cytotoxic T-cell activity. Deubiquitination of IFI16 at lysine 143 and lysine 561 was crucial for FAM135B-mediated activation of the STING pathway. These findings reveal that FAM135B regulates the IFI16-dependent STING pathway and subsequent immune activation. FAM135B may represent a potential predictor of ICB therapeutic responses for patients with TNBC. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nTriple-negative breast cancer (TNBC) is characterized by a lack of estrogen receptor and progesterone receptor expression, as well as the absence of HER2 amplification (1). This subtype of breast cancer is the most aggressive among the different subtypes and exhibits the worst prognosis (2). Because of limited therapeutic targets, chemotherapy is currently the standard treatment for TNBC (3). However, the efficacy of these cytotoxic agents in patients with TNBC is often suboptimal, highlighting the need to develop more effective treatment strategies. The emergence of immune checkpoint blockade (ICB) therapies targeting PD-L1 and PD-1 has revolutionized the treatment of many cancers, yielding substantial improvement in patient outcomes (4, 5). Nonetheless, only approximately 15% of patients with early-stage TNBC derive durable benefits from ICB in combination with other treatments (6). Consequently, elucidating the mechanisms underlying immune responses in TNBC is vital for identifying informative biomarkers for ICB response and developing effective combination therapy strategies.  \n1Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China. 2Department of Pathology, Guangdong Province Key Laboratory of Molecular Tumor Pathology, School of Basi","cbCaiiyxKTRh5Fvw","https://ap.wps.com/l/cbCaiiyxKTRh5Fvw","pdf",24343869,15,"English","# Introduction\n## Triple-negative breast cancer and immune checkpoint blockade\n## Rationale for identifying cytotoxic T-cell activation genes","[{\"question\":\"What role does FAM135B play in triple-negative breast cancer immunity?\",\"answer\":\"FAM135B acts as a regulator of antitumor immunity in TNBC by activating cytotoxic T cells and supporting effective immune checkpoint blockade responses.\"},{\"question\":\"How does FAM135B activate the STING pathway?\",\"answer\":\"FAM135B interacts with IFI16 and inhibits its ubiquitination and proteasomal degradation, initiating IFI16-dependent STING signaling that increases cytotoxic T-cell activity.\"},{\"question\":\"Why are IFI16 deubiquitination sites important?\",\"answer\":\"Deubiquitination of IFI16 at lysine 143 and lysine 561 is crucial for FAM135B-mediated activation of the STING pathway and subsequent immune activation.\"}]","FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer - Inhibits Cytotoxic T-cell Activity | PDF",1790147341,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/887227bdfbebf9321130a07e45dc8331.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e94857b06212f52f6d90169609dcc7a.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6ee8137d4570c10e3eb7947e095ac70.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d118583fad45d4884f33181c7b8bc0f.webp",980,1311]